

# 36<sup>th</sup> World Cancer Conference & 3<sup>rd</sup> Edition of International Conference on **Colorectal Cancer**

October 11-13, 2018 Zurich, Switzerland

## A novel innate immune checkpoint inhibitor protein in tumor microenvironment

Jeong Hwa Park<sup>1</sup>, Yeong-Min Park<sup>1</sup> and Tae Heung Kang<sup>1</sup><sup>1</sup>Konkuk University, South Korea

After cancer treatment using chemotherapy and radiotherapy, tumor microenvironment continually occurs inflammation, which depend on damage-associated molecular pattern (DAMPs) released from apoptotic tumor cells. In this case, tumor microenvironment is regarded as inflammation zone and induce various immune cells infiltration, pro- and anti-inflammatory cytokines production and interaction between immune cells and cancer cells. These, a dynamic and complex microenvironment induce a favorable state for tumor growth. Thus, recent studies assert that it is important to regulate excessively increased inflammatory response in the tumor microenvironment accordingly. Annexin V is a Ca<sup>2+</sup>-dependent phospholipid binding protein and known to bind to exposed phosphatidylserine on the apoptotic cells. Several groups and our study have recently demonstrated that annexin V has anti-inflammatory effects by inhibiting bone-marrow derived dendritic cell (BMDCs) activation and pro-inflammatory cytokine production. So, we suggest that Annexin V as a therapeutic approach for controlling inflammatory response in cancer patients having increased inflammation in tumor microenvironment. Therapeutic efficacy was demonstrated activation of tumor-specific CD<sup>8+</sup> T cells ( $P < 0.001$ ), inhibition of tumor growth ( $P < 0.05$ ) and increase of survival ( $P < 0.05$ ) in tumor bearing mouse compared to control. AnnexinV protein administration was decreased significantly TGF-beta 1 cytokine production ( $P < 0.001$ ) and immunosuppressive cells infiltration ( $P < 0.001$ ) in tumor microenvironment compared to non-treated group. We identified another role of Annexin V protein, which has capacity of apoptotic tumor cell target, as an innate immune check point inhibitor in tumor microenvironment. This results could primarily pave the road for the development of anti-tumor immunotherapy.

junghwa0814@hanmail.net

Notes: